New insights into the interaction between m6A modification and lncRNA in cancer drug resistance

Abstract

Drug resistance is perhaps the greatest obstacle in improving outcomes for cancer patients, leading to recurrence, progression and metastasis of various cancers. Exploring the underlying mechanism worth further study. N6‐methyladenosine (m6A) is the most common RNA modification found in eukaryotes, playing a vital role in RNA translation, transportation, stability, degradation, splicing and processing. Long noncoding RNA (lncRNA) refers to a group of transcripts that are longer than 200 nucleotides (nt) and typically lack the ability to code for proteins. LncRNA has been identified to play a significant role in regulating multiple aspects of tumour development and progression, including proliferation, metastasis, metabolism, and resistance to treatment. In recent years, a growing body of evidence has emerged, highlighting the crucial role of the interplay between m6A modification and lncRNA in determining the sensitivity of cancer cells to chemotherapeutic agents. In this review, we focus on the recent advancements in the interaction between m6A modification and lncRNA in the modulation of cancer drug resistance. Additionally, we aim to explore the underlying mechanisms involved in this process. The objective of this review is to provide valuable insights and suggest potential future directions for the reversal of chemoresistance in cancer.

Clinical role of the long non‑coding RNA, EGFR‑AS1, in patients with cancer: A systematic review and meta‑analysis

“…Long non-coding RNAs (lncRNAs) are >200 bp RNAs that do not encode proteins, which have been demonstrated to fully participate in the metabolic processes of cancer cells ( 1 ). Compared with RNA-encoding proteins, lncRNAs possess a greater reservoir of transcriptional information ( 2 ). EGFR-AS1 is a 2,821-kb lncRNA located on human chromosome 7; its locus is in the opposite direction of EGFR gene transcription according to the UCSC database ( ).…”

Identification of potential novel N6-methyladenosine effector-related lncRNA biomarkers for serous ovarian carcinoma: a machine learning-based exploration in the framework of 3P medicine

“…Several studies have reported interactions between m 6 A modifications and lncRNAs ( Ma et al, 2019 ; Yi et al, 2020 ). m 6 A modifications affect the functions of lncRNAs through an m 6 A-switch, thereby inhibiting transcription, mediating competing endogenous RNA (ceRNA) effects, and regulating lncRNA stability or degradation ( Jin and Fan, 2023 ; Mehrdad et al, 2023 ); for example, METTL14-mediated m 6 A methylation and TINCR lncRNA regulation in pyroptosis and diabetic cardiomyopathy ( Meng et al, 2022 ). The combination of the m 6 A reader YTHDC1 and lncRNA XIST promotes lncRNA XIST -mediated gene repression ( Patil et al, 2016 ).…”

“…Given the complexity of the mechanisms underlying the interaction between m 6 A modifications and lncRNAs, an increasing number of studies have investigated their potential applications in the diagnosis, prognosis, and treatment of tumors and determining the sensitivity of cancer cells to chemotherapeutic agents ( Jin and Fan, 2023 ). A previous study accurately predicted the 5-year survival of patients with GC by stratifying their overall survival (OS) using a risk prediction model based on 11 m 6 A-associated lncRNAs ( Wang H et al, 2021 ).…”